China Universal Asset Management Co. Ltd. Increases Stock Position in Dynavax Technologies Co. (NASDAQ:DVAX)

China Universal Asset Management Co. Ltd. increased its stake in shares of Dynavax Technologies Co. (NASDAQ:DVAX) by 10.6% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 27,873 shares of the biopharmaceutical company’s stock after purchasing an additional 2,669 shares during the period. China Universal Asset Management Co. Ltd.’s holdings in Dynavax Technologies were worth $356,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in DVAX. Marshall Wace LLP bought a new stake in shares of Dynavax Technologies in the second quarter worth $902,000. Millennium Management LLC purchased a new position in shares of Dynavax Technologies in the second quarter worth approximately $17,615,000. The Manufacturers Life Insurance Company grew its position in Dynavax Technologies by 6.4% during the second quarter. The Manufacturers Life Insurance Company now owns 67,854 shares of the biopharmaceutical company’s stock valued at $762,000 after buying an additional 4,069 shares during the period. Algert Global LLC purchased a new stake in Dynavax Technologies during the second quarter valued at approximately $140,000. Finally, Sanctuary Advisors LLC bought a new position in Dynavax Technologies in the second quarter worth approximately $182,000. Institutional investors own 96.96% of the company’s stock.

Wall Street Analysts Forecast Growth

DVAX has been the subject of several analyst reports. HC Wainwright upped their price objective on Dynavax Technologies from $29.00 to $31.00 and gave the stock a “buy” rating in a research note on Tuesday, January 14th. StockNews.com raised Dynavax Technologies from a “hold” rating to a “buy” rating in a report on Tuesday, January 14th.

Dynavax Technologies Stock Performance

DVAX opened at $13.05 on Monday. The company has a 50 day simple moving average of $12.78 and a two-hundred day simple moving average of $11.82. The company has a debt-to-equity ratio of 0.33, a current ratio of 13.23 and a quick ratio of 12.34. The firm has a market cap of $1.72 billion, a P/E ratio of 100.39 and a beta of 1.34. Dynavax Technologies Co. has a 1-year low of $9.74 and a 1-year high of $13.89.

Dynavax Technologies (NASDAQ:DVAX) last issued its earnings results on Thursday, November 7th. The biopharmaceutical company reported $0.12 earnings per share for the quarter, topping the consensus estimate of $0.10 by $0.02. The company had revenue of $80.63 million during the quarter, compared to the consensus estimate of $83.64 million. Dynavax Technologies had a net margin of 7.85% and a return on equity of 3.19%. During the same quarter in the prior year, the firm posted $0.10 EPS. Equities analysts forecast that Dynavax Technologies Co. will post 0.2 earnings per share for the current fiscal year.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.